Use of ARN-509 in Prostate Cancer

Publication
Article
Special ReportsGenitourinary (Issue 2)
Issue 2

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the use of ARN-509 and its efficacy in treating prostate cancer.

Articles in this issue
Use of ARN-509 in Prostate Cancer
Use of ARN-509 in Prostate Cancer
Abiraterone Plus Low-Dose Prednisone Lowers PSA in High-Risk M0 CRPC
Abiraterone Plus Low-Dose Prednisone Lowers PSA in High-Risk M0 CRPC
Multiparametric MRI Effective, Affordable for Prostate Cancer Detection
Multiparametric MRI Effective, Affordable for Prostate Cancer Detection
Study Illuminates Role of AR-V7 in Carcinogenesis
Study Illuminates Role of AR-V7 in Carcinogenesis
Long-Term Exposure to Low-Dose Prednisone With Abiraterone Acetate for mCRPC
Long-Term Exposure to Low-Dose Prednisone With Abiraterone Acetate for mCRPC
PSA Screening Drops 50% Following USPSTF Recommendation
PSA Screening Drops 50% Following USPSTF Recommendation
Urine-Based Diagnostic Effectively Identifies Prostate Cancer
Urine-Based Diagnostic Effectively Identifies Prostate Cancer
Trends in PSA Utilization in Primary Care Physicians
Trends in PSA Utilization in Primary Care Physicians
AR-V7 as a Biomarker in CRPC
AR-V7 as a Biomarker in CRPC
Recent Videos
Related Content
FDA Accepts sNDA for Darolutamide Plus ADT in mHSPC

FDA Accepts sNDA for Darolutamide Plus ADT in mHSPC

Jordyn Sava
November 21st 2024
Article

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Read More

Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen

Novel immunotherapy FK-PC101 Explored in Prostate Cancer Trial

Novel immunotherapy FK-PC101 Explored in Prostate Cancer Trial

Jordyn Sava
November 18th 2024
Article

The phase 2 CELLVX-230 trial is assessing the potential of FK-PC101 to prevent prostate cancer recurrence and delay additional treatments post-surgery.

Read More

Dizman’s Global Pursuit to Cancer Research and Understanding

Dizman’s Global Pursuit to Cancer Research and Understanding

Jordyn Sava;Nazli Dizman, MD
April 1st 2024
Podcast

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Listen

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Jonah Feldman
November 15th 2024
Article

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

Read More

FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research

FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research

Jordyn Sava
November 15th 2024
Article

The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.

Read More